Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Liabilities and Shareholders Equity: 2021-2022

Historic Liabilities and Shareholders Equity for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $52.4 million.

  • Cardiol Therapeutics' Liabilities and Shareholders Equity rose 107.93% to $52.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $259.8 million, marking a year-over-year change of. This contributed to the annual value of $70.1 million for FY2021, which is N/A change from last year.
  • Cardiol Therapeutics' Liabilities and Shareholders Equity amounted to $52.4 million in Q3 2022, which was down 10.02% from $58.2 million recorded in Q2 2022.
  • In the past 5 years, Cardiol Therapeutics' Liabilities and Shareholders Equity ranged from a high of $79.4 million in Q1 2022 and a low of $25.2 million during Q3 2021.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $55.3 million (2022), whereas its average is $53.6 million.
  • Data for Cardiol Therapeutics' Liabilities and Shareholders Equity shows a peak YoY surged of 107.93% (in 2022) over the last 5 years.
  • Cardiol Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $69.7 million in 2021, then spiked by 107.93% to $52.4 million in 2022.
  • Its last three reported values are $52.4 million in Q3 2022, $58.2 million for Q2 2022, and $79.4 million during Q1 2022.